Literature DB >> 73970

Fibroblast interferon in HBsAg-positive chronic active hepatitis.

W Weimar, R A Heijtink, S W Schalm, M van Blankenstein, H Schellekens, N Masurel, V G Edy, A Billiau, P De Somer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 73970     DOI: 10.1016/s0140-6736(77)92682-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Antiviral agents: action and clinical use.

Authors:  T W Chang; D R Snydman
Journal:  Drugs       Date:  1979-11       Impact factor: 9.546

Review 2.  Interferon: therapeutic fact or fiction for the '80s?

Authors:  G M Scott; D A Tyrrell
Journal:  Br Med J       Date:  1980-06-28

3.  Influence of (+)-cyanidanol-3 on the leukocyte migration inhibition test carried out in the presence of purified protein derivative and hepatitis B surface antigen.

Authors:  J J Vallotton; P C Frei
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

4.  Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection.

Authors:  Marc S Weinberg; Patrick Arbuthnot
Journal:  Genome Med       Date:  2010-04-28       Impact factor: 11.117

5.  Human fibroblast interferon for clinical trials: pharmacokinetics and tolerability in experimental animals and humans.

Authors:  A Billiau; P De Somers; V G Edy; E De Clercq; H Heremans
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

Review 6.  The clinical application of fibroblast interferon--an overview.

Authors:  A Billiau
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

Review 7.  Interferons at age 50: past, current and future impact on biomedicine.

Authors:  Ernest C Borden; Ganes C Sen; Gilles Uze; Robert H Silverman; Richard M Ransohoff; Graham R Foster; George R Stark
Journal:  Nat Rev Drug Discov       Date:  2007-12       Impact factor: 84.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.